Ascendis Pharma A/S ASND 深 滬
等待開盤 09-23 09:30:00 美东时间
237.57
-0.020
-0.01%
華盛通- 最 高240.69
- 今 開239.09
- 成交量 54.83万股
- 最 低 234.67
- 昨 收 237.59
- 總市值 156.28亿
- 52周最高 282.15
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 186.054
- 委 比 76.79%
- 總股本 6578.34万
- 歷史最高 282.15
- 量 比 0.36
- 振 幅 2.53%
- 歷史最低 11.92
- 每 手 1
- 風險率 20.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多诺和诺德终止 GLP-1 月制剂合作
（来源：求实药社） 近日，Ascendis Pharma A/S 宣布，公司将重新获得开发、生产和销售基于 TransCon 技术的代谢和心血管疾病（包括肥胖症...
09-17 12:00
诺和，终止重磅合作！
近日，诺和诺德刚刚宣布将“Novo Nordisk”正式简化为“Novo”，配合“The Novo Way”的全新品牌框架，向外界传递一个更敏捷、更聚焦的信号...
09-16 16:34
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that the company will regain rights to certain TransCon technology-based programs and a share buyback. ASND Regains TransCon Rights In Metabolic And Cardiovascular Programs Ascendis said all rights to Tran...
09-16 01:56
Ascendis Pharma Authorizes Up To $400M Share Repurchase Program
Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program). Purchases under the planned Share Repurchase Program may be made from time to time, in such amoun...
09-15 06:01
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an annualized basis producing an average annual return of 29.64%. Currently, Ascendis Pharma has a market capitalization of $17.43 billion. Buying $100 In ASND: If an investor had bought $100 of ASND stock ...
09-15 05:30
Ascendis Announces Planned $400 Million Share Repurchase Program
Ascendis Pharma A/S announced that its Board of Directors has authorized the Company to repurchase up to $400 million of its ordinary shares under a Share Repurchase Program. The Company may repurchase shares at various times and through multiple methods, including open market purchases, block trades, and 10b5-1 plans, depending on market conditions and other factors. The program does not commit the Company to repurchasing a specific number of sh...
09-14 22:00
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
Ascendis Pharma announced it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity, following the termination of its collaboration with Novo Nordisk. Ascendis plans to initiate multiple programs, including advancing once-monthly TransCon Semaglutide for obesity and type 2 diabetes, aiming to address unmet medical needs.
09-14 22:00
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
Ascendis Pharma A/S (NASDAQ:ASND) on Wednesday announced Week 52 data from the open-label sentinel cohort of its reACHin trial. The data showed that once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants w...
09-10 21:52
